Citations

Clear

4 citation(s) found for "Garg, Nikita".

Deep Learning Model for Histologic Diagnosis of Dysplastic Barrett's Esophagus: Multisite Cohort External Validation
Codipilly, Don C. , Faghani, Shahriar , Vogelsang, David C. , Erickson, Bradley J. , Garg, Nikita , Lewis, Jason , Leggett, Cadman L. , Konda, Vani J. , Diffalha, Sameer Al , Peter, Shajan, Brinkerhoff, Brian , Wong, Mary , Otaki, Fouad , Katzka, David A. , Wani, Sachin , Shaheen, Nicholas J. , Iyer, Prasad G. , Codipilly, Don Chamil , Vogelsang, David, Erickson, Bradley J , Hagen, Catherine E , Leggett, Cadman L , Konda, Vani , Wong, Mary , Otaki, Fouad , Katzka, D A , Faghani, Shahriar , Hagen, Catherine E. , Patil, Pallavi

Mayo Clinic

American Journal of Gastroenterology | April 23, 2025 | Volume: 121 | Issue: 4 | Pages: 863-870

10.14309/ajg.0000000000003495 | PMID 40267276 Get It

INTRODUCTION: The risk of progression to esophageal adenocarcinoma in Barrett's esophagus (BE) increases with advancing degrees of dysplasia. There is a critical need to improve the diagnosis of BE dysplasia, given substantial interobserver variability and overcalls of dysplasia during manual community pathologist reads. We aimed to externally validate a previously cross-validated BE dysplasia diagnosis deep learning model (BEDDLM) that predicts dysplasia grade on whole slide images (WSIs). METHODS: We digitized nondysplastic BE (NDBE), low-grade (LGD), and high-grade dysplasia (HGD) histology slides from 3 external academic centers. A consensus read by 2 expert study pathologists was used as the criterion standard. Slide stain characteristics were normalized using cycle-generative adversarial networks. WSIs were assessed by BEDDLM using an ensemble approach, combining a “You Only Look Once” model followed by a ResNet101 classifier model. RESULTS: We included 489 WSIs. Consensus histopathology revealed 232 NDBE, 117 LGD, and 140 HGD WSIs. The mean age (SD) was 66.9 (11.4) years; 413 (84.7%) were men. Using the BEDDLM ensemble model, sensitivity and specificity for NDBE were 73.3% (95% confidence interval [CI]: 67.09%–78.85%) and 93.4% (95% CI: 89.62%–96.10%); for LGD, 84.6% (95% CI: 76.78%–90.62%) and 80.6% (95% CI: 76.26%–84.54%); and for HGD, 80.7% (95% CI: 73.19%–86.89%) and 94.8% (95% CI: 91.97%–96.91%), respectively. The F1 score was 0.81, 0 0.69, and 0.83 for NDBE, LGD, and HGD, respectively. DISCUSSION: Our externally validated deep learning model demonstrates substantial accuracy for the diagnosis of BE dysplasia grade on WSIs.
Journey to complete remission of dysplasia and intestinal metaplasia after ESD and EMR of Barrett’s esophagus-related neoplasia
Joseph, Abel , Vantanasiri, Kornpong , Garg, Nikita , Codipilly, Don C. , Wang, Kenneth T. , Harmsen, William S. , Jang, Sunguk, Iyer, Prasad G. , Bhatt, Amit, Bhatt, Amit , Leggett, Cadman, Iyer, Prasad, Bhatt, Amit , Goyal, Rohit, Leggett, Cadman L. , Vargo, John Joseph

Mayo Clinic

Endoscopy International Open | March 18, 2025 | Volume: 13 | Issue: CP | Pages: No page available

10.1055/a-2422-2815 | PMID 40376017 Get It

AbstractAlthough endoscopic submucosal dissection (ESD) is associated with higher en-bloc and R0 resection rates than cap-assisted endoscopic mucosal resection (cEMR), its comparative impact on achieving complete remission of dysplasia (CRD) and intestinal metaplasia (CRIM) in BE endoscopic eradication therapy (EET) is not well defined. We aimed to compare the journey of patients from initial endoscopic resection (ER) with ESD and cEMR to achieving CRD and CRIM.Patients undergoing ESD or cEMR followed by ablation for BE neoplasia at two academic institutions in the United States were included. Primary outcomes included CRD and CRIM rates following ER in the two groups. Secondary outcomes included the number of resection/ablative procedures from initial ER to achieving CRD and CRIM. Inverse probability treatment weighting (IPTW) was used to balance confounding variables between groups.A total of 801 patients (606 cEMR, 195 ESD) were included. ESD group patients had higher en-bloc resection rates (ESD 94.4%, cEMR 44.7%). Higher rates of CRD were observed in patients undergoing initial ESD (HR 1.53, P < 0.01). With time-to-event and IPTW analyses, rates of achieving CRD and CRIM were comparable between the groups. There were no significant differences in mean number of endoscopic resection or ablative procedures among patients undergoing initial cEMR resection compared with those treated with initial ESD.Despite larger lesion sizes and more cancers in patients undergoing ESD, the EET journey to achieving CRD and CRIM was comparable to that in patients receiving cEMR. Prospective studies are required to further study differences between these two treatment approaches.
Rates of Recurrent Intestinal Metaplasia and Dysplasia After Successful Endoscopic Therapy of Barrett's Neoplasia by Endoscopic Mucosal Resection vs Endoscopic Submucosal Dissection and Ablation: A Large North American Multicenter Cohort
Vantanasiri, Kornpong , Joseph, Abel , Sachdeva, Karan , Goyal, Rohit , Garg, Nikita , Adoor, Dayyan , Kamboj, Amrit K. , Codipilly, Don C. , Leggett, Cadman L. , Wang, Kenneth K. , Harmsen, William S. , Hayat, Umar , Chak, Amitabh , Bhatt, Amit , Iyer, Prasad G. , Codipilly, Don Chamil , Leggett, Cadman L , Bhatt, Amit , Vantanasiri, Kornpong

Mayo Clinic

American Journal of Gastroenterology | April 8, 2024 | Volume: 119 | Issue: 9 | Pages: 1831-1840

10.14309/ajg.0000000000002798 | PMID 38587280 Get It

INTRODUCTION: Endoscopic eradication therapy (EET) combining endoscopic resection (ER) with endoscopic mucosal resection (EMR) or endoscopic submucosal dissection (ESD) followed by ablation is the standard of care for the treatment of dysplastic Barrett's esophagus (BE). We have previously shown comparable rates of complete remission of intestinal metaplasia (CRIM) with both approaches. However, data comparing recurrence after CRIM are lacking. We compared rates of recurrence after CRIM with both techniques in a multicenter cohort. METHODS: Patients undergoing EET achieving CRIM at 3 academic institutions were included. Demographic and clinical data were abstracted. Outcomes included rates and predictors of any BE and dysplastic BE recurrence in the 2 groups. Cox-proportional hazards models and inverse probability treatment weighting (IPTW) analysis were used for analysis. RESULTS: A total of 621 patients (514 EMR and 107 ESD) achieving CRIM were included in the recurrence analysis. The incidence of any BE (15.7, 5.7 per 100 patient-years) and dysplastic BE recurrence (7.3, 5.3 per 100 patient-years) were comparable in the EMR and ESD groups, respectively. On multivariable analyses, the chances of BE recurrence were not influenced by ER technique (hazard ratio 0.87; 95% confidence interval 0.51–1.49; P = 0.62), which was also confirmed by IPTW analysis (ESD vs EMR: hazard ratio 0.98; 95% confidence interval 0.56–1.73; P = 0.94). BE length, lesion size, and history of cigarette smoking were independent predictors of BE recurrence. DISCUSSION: Patients with BE dysplasia/neoplasia achieving CRIM, initially treated with EMR/ablation, had comparable recurrence rates to ESD/ablation. Randomized trials are needed to confirm these outcomes between the 2 ER techniques.
Clinical Outcomes After Endoscopic Management of Low-Risk and High-Risk T1a Esophageal Adenocarcinoma: A Multicenter Study
Kamboj, Amrit K. , Vantanasiri, Kornpong , Sachdeva, Karan , Passe, Melissa, Lansing, Ramona, Garg, Nikita , Chandi, Paras Singh , Ramirez, Francisco C. , Kahn, Allon , Wolfsen, Herbert C. , Krishna, Murli , Pai, Rish K. , Hagen, Catherine E. , Lee, Hee Eun , Wang, Kenneth K. , Leggett, Cadman L. , Iyer, Prasad G. , Vantanasiri, Kornpong , Chandi, Paras S , Kahn, Allon , Fukami, Norio , Hagen, Catherine, Leggett, Cadman L , Hagen, Catherine E , Goyal, Rohit, Fukami, Norio

Mayo Clinic

American Journal of Gastroenterology | October 5, 2023 | Volume: 119 | Issue: 4 | Pages: 662-670

10.14309/ajg.0000000000002554 | PMID 37795907 Get It

INTRODUCTION: Endoscopic eradication therapy (EET) is standard of care for T1a esophageal adenocarcinoma (EAC). However, data on outcomes in high-risk T1a EAC are limited. We assessed and compared outcomes after EET of low-risk and high-risk T1a EAC, including intraluminal EAC recurrence, extraesophageal metastases, and overall survival. METHODS: Patients who underwent EET for T1a EAC at 3 referral Barrett's esophagus endotherapy units between 1996 and 2022 were included. Patients with submucosal invasion, positive deep margins, or metastases at initial diagnosis were excluded. High-risk T1a EAC was defined as T1a EAC with poor differentiation and/or lymphovascular invasion, with low-risk disease being defined without these features. All pathology was systematically assessed by expert gastrointestinal pathologists. Baseline and follow-up endoscopy and pathology data were abstracted. Time-to-event analyses were performed to compare outcomes between groups. RESULTS: One hundred eighty-eight patients with T1a EAC were included (high risk, n = 45; low risk, n = 143) with a median age of 70 years, and 84% were men. Groups were comparable for age, sex, Barrett's esophagus length, lesion size, and EET technique. Rates of delayed extraesophageal metastases (11.1% vs 1.4%) were significantly higher in the high-risk group ( P = 0.02). There was no significant difference in the rates of intraluminal EAC recurrence ( P = 0.79) and overall survival ( P = 0.73) between the 2 groups. DISCUSSION: Patients with high-risk T1a EAC undergoing successful EET had a substantially higher rate of extraesophageal metastases compared with those with low-risk T1a EAC on long-term follow-up. These data should be factored into discussions with patients while selecting treatment approaches. Additional prospective data in this area are critical.